Triomics, an AI company focused on oncology data, has secured $22 million in Series B funding. The round was led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed, and Y Combinator, along with strategic backers Oncology Ventures and Precision Health Informatics. This brings the company's total funding to over $36 million.
AI Tackles Oncology's Information Overload
The capital infusion will be used to expand Triomics' AI platform across cancer centers and life sciences organizations. The company's technology aims to operationalize complex clinical information, a significant challenge in cancer care.
Triomics is already working with major institutions including Memorial Sloan Kettering Cancer Center, MD Anderson, Yale Cancer Center, and Texas Oncology.
"Oncology faces an information burden at a scale legacy systems were never designed to handle," said Sarim Khan, co-founder and CEO of Triomics. "We built Triomics to turn that complexity into usable intelligence inside the workflow, purpose-built for oncology."
The platform uses AI agents to process longitudinal patient records, converting unstructured data into structured, verifiable insights delivered directly into clinical workflows. This approach supports proactive clinical trial matching, pre-visit chart review, and data abstraction for research and operations.